Hospital Universitari de Bellvitge

The Neuromuscular Unit of the Bellvitge University Hospital, a tertiary centre for a population of more than 2 million inhabitants, (NMD-HUB) is part of the Neurology Department and currently is working in coordination with the group of neurological diseases and neurogenetics and the neurometabolic disease group of the Bellvitge Biomedical Research Institute (IDIBELL), the neuroscience area of the department of Clinical Sciences of the Faculty of Medicine of the University of Barcelona. In addition, members of the Unit are integrated into both CIBERNED and AGAUR groups. The NMD-HUB is differentiated in subareas with specific coordinators in each of them: 1. Muscle diseases 2. Peripheric nerve diseases 3. motor neuron diseases 4. neuromuscular junction diseases 5. Neurophysiological studies on neuromuscular disorders. The Unit also includes the Amotrophic Lateral Sclerosis Functional Unit and the Family Amyloidosis Functional Unit.
The NMD-HUB, in turn, is included in the Minority Diseases Attention Group of the Bellvitge University Hospital, which includes all the professionals involved in the diagnosis, management, care and treatment of low prevalence diseases in our centre.
At present, the HUB-NMD is a reference center in the Network of Units of Clinical Expertise in Catalonia (XUEC) and Centers, Services and Reference Units in Spain (CSUR) for rare neuromuscular diseases.


Group membership

Hospital Universitari de Bellvitge participates in the following groups…

Specialised Groups

Muscle diseases
Peripheral Nerve Disease
Motor Neuron Disease
Neuromuscular Junction Defects

Cross Cutting Specialised Groups


Hospital Universitari de Bellvitge is registered with the Care and Trial Site Registry

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit